About Htg molecular diagnostics
HTG Molecular Diagnostics: Revolutionizing Precision Medicine with Next-Generation Sequencing
HTG Molecular Diagnostics is a leading provider of molecular profiling solutions that enable precision medicine. The company's next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously analyze multiple biomarkers from a single sample. This allows for more accurate diagnoses, personalized treatment plans, and improved patient outcomes.
Founded in 1997 as High Throughput Genomics, HTG Molecular Diagnostics has since evolved into a cutting-edge biotechnology company that specializes in developing innovative molecular diagnostic assays. The company's proprietary technology platform is based on its HTG EdgeSeq chemistry, which enables the detection of RNA biomarkers from various sample types using NGS.
The HTG EdgeSeq system offers several advantages over traditional methods of molecular profiling. For one thing, it eliminates the need for labor-intensive manual processes such as RNA extraction and library preparation. Instead, the system automates these steps using microfluidic cartridges that contain all the necessary reagents for each assay.
Another advantage of the HTG EdgeSeq system is its ability to analyze multiple biomarkers simultaneously from a single sample. This means that clinicians can obtain more comprehensive information about a patient's disease status than they would be able to with traditional methods.
HTG Molecular Diagnostics' technology has been validated in numerous clinical studies across various disease areas such as oncology, immunology, infectious diseases and others. In fact their technology has been used by researchers worldwide to develop new diagnostic tests or improve existing ones.
One example of how HTG Molecular Diagnostics' technology is being used in precision medicine is through their collaboration with Qiagen on developing companion diagnostics for immuno-oncology therapies targeting PD-L1/PD-1 pathway inhibitors like pembrolizumab (Keytruda) or nivolumab (Opdivo). These drugs have shown remarkable efficacy against certain cancers but only work in patients whose tumors express high levels of PD-L1 protein on their surface cells; therefore identifying those patients who will benefit most from these treatments requires accurate testing which can be done by using companion diagnostics developed by companies like Qiagen or Roche Pharma AG .
In addition to its core business of providing molecular profiling solutions for precision medicine applications , HTG also offers custom assay development services to pharmaceutical companies looking to develop new drugs or improve existing ones . Their expertise in designing assays tailored specifically towards drug discovery makes them an ideal partner for any pharmaceutical company looking to accelerate their research efforts .
Overall , HTG Molecular Diagnostics represents an exciting opportunity for investors interested in biotechnology companies at forefronts of innovation . With its cutting-edge technology platform , strong partnerships with industry leaders like Qiagen & Roche Pharma AG , proven track record validating clinical utility across different disease areas including oncology & immunology among others ; this company has positioned itself well within rapidly growing field Precision Medicine where demand continues outpace supply due limited availability reliable diagnostic tools capable accurately identifying patients who will benefit most from targeted therapies .